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Aims:Wehave investigated the role ofmusclemass, natriuretic peptides and adipokines in explaining the obesity
paradox.
Background: The obesity paradox relates to the association between obesity and increased survival in patients
with coronary heart disease (CHD) or heart failure (HF).
Methods: Prospective study of 4046 men aged 60–79 years followed up for a mean period of 11 years, during
which 1340 deaths occurred. The men were divided according to the presence of doctor diagnosed CHD and
HF: (i) no CHD or HF ii), with CHD (no HF) and (iii) with HF.
Results: Overweight (BMI 25–9.9 kg/m2) and obesity (BMI ≥ 30 kg/m2) were associated with lower mortality
risk compared to men with normal weight (BMI 18.5–24.9 kg/m2) in those with CHD [hazards ratio (HR) 0.71
(0.56,0.91) and 0.77 (0.57,1.04); p = 0.04 for trend] and in those with HF [HR 0.57 (0.28,1.16) and 0.41
(0.16,1.09; p = 0.04 for trend). Adjustment for muscle mass and NT-proBNP attenuated the inverse association
in those with CHD (no HF) [HR 0.78 (0.61,1.01) and 0.96 (0.68,1.36) p = 0.60 for trend) but made minor differ-
ences to thosewith HF [p = 0.05]. Leptin related positively tomortality inmenwithout HF but inversely tomor-
tality in those with HF; adjustment for leptin abolished the BMI mortality association in men with HF [HR 0.82
(0.31,2.20) and 0.99 (0.27,3.71); p = 0.98 for trend].
Conclusion: The lower mortality risk associated with excess weight in men with CHD without HF may be due to
higher muscle mass. In men with HF, leptin (possibly reﬂecting cachexia) explain the inverse association.© 2013 The Authors. Published by Elsevier Ireland Ltd.Open access under CC BY-NC-ND license. 1. Introduction
Despite the well-established adverse association between obesity
and risk of developing cardiovascular disease and heart failure (HF), aretic peptide;HF, Heart failure;
; CRP, C-reactive protein; WC,
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namethee).
land Ltd. Open access under CC BY-NClarge body of evidence indicates that overweight and obesity are associ-
ated with increased survival in patients with HF [1–3] an unexpected
ﬁnding commonly termed the ‘obesity paradox’. Numerous investiga-
tors andmeta-analysis of studies in cohorts with coronary heart disease
(CHD) have also demonstrated this paradoxical relationship in patients
with CHD [4–8] although this has not been seen in all studies after ad-
justment for confounders [9,10]. The aetiology of this paradoxical asso-
ciation remains largely unexplained but a number of explanations have
been proposed [4,11,12]. BMI is a poor marker of body fat and does not
distinguish between fat and lean body mass which has been associated
with increasedmortality [13]. Abdominal obesity has been suggested as
a better marker of obesity risk. Indeed, meta-analysis of cohorts in CHD
has shown positive associations betweenWC and mortality [14]. In HF,
the obesity paradoxmay be driven by the deleterious effects of cachexia
(i.e. weight loss) reﬂecting the combined loss of muscle and adipose tis-
sues [15]. It has also been postulated that several physiologic mecha-
nisms may explain the protective effect of a higher BMI on mortality
[12]. NT-proBNP levels are lower in overweight and obese patients;
lower NT-proBNP predicts lower mortality [12,16]. Another possible-ND license. 
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adipose tissue [12,15]. Adipose tissue produces leptin which experi-
mental studies suggest may have protective effects in HF [17] and
adiponectin is decreased in obesity; lower concentrations of
adiponectin have been associated with lower mortality in patients
with CHD or HF [18–20]. However few population studies to date
have examined the possible role of lean muscle mass, adipokines (lep-
tin, adiponectin) and NT-proBNP in explaining the obesity paradox, al-
though previous studies suggest that NT-proBNP and adiponectin may
explain the obesity paradox in HF [18,21]. In a previous report, we ob-
served a positive association between BMI andmortality in older adults
without HF once muscle mass had been taken into account [13]. Howev-
er, the association of BMI and mortality in men with CHD or HF has not
been speciﬁcally examined. We have examined the association between
BMI and all-causemortality separately inmenwith diagnosed CHDwith-
out HF and inmenwithHF (with orwithout CHD) and examined the role
of muscle mass, adipocytes and NT-proBNP in explaining the obesity
mortality paradox in these two groups. To see whether the obesity para-
dox is speciﬁc to those with established CHD or HF the association be-
tween BMI and mortality is also presented in those without CHD or HF.
2. Subjects and methods
The British Regional Heart Study is a prospective study of cardiovascular disease in-
volving 7735 men aged 40–59 years selected from the age–sex registers of one general
practice in each of 24 British towns, who were screened between 1978 and 1980 [22]. In
1998–2000, all surviving men, now aged 60–79 years, were invited for a 20th year
follow-up examination. Ethical approval was provided by all relevant local research ethics
committees. All men provided informed written consent to the investigation, which was
carried out in accordance with the Declaration of Helsinki. All men completed a mailed
questionnaire providing information on their lifestyle and medical history, had a physical
examination and provided a fasting blood sample. The samples were frozen and stored at
−20 °C on the day of collection and transferred in batches for storage at −70 °C until
analysis, carried out after no more than one freeze–thaw cycle. 4252 men (77% of survi-
vors) attended for examination. 12 lead electrocardiograms were recorded using a
Siemens Sicard 460 instrument and were analyzed and coded in accordance with
Minnesota Coding deﬁnitions at the University of Glasgow ECG core laboratory based at
Glasgow Royal Inﬁrmary [23].
2.1. Anthropometric measurements
Measurements at re-examination (1998–2000) included height, weight, waist cir-
cumference, triceps skinfold thickness and mid-upper arm circumference (MUAC). The
waist measurement was taken from the midpoint between the iliac crest and the lower
ribsmeasured at the sides. Bodymass index (BMI;weight/height2 in kg/m2) was calculat-
ed for each man. Mid arm muscle circumference (MAMC) was calculated as
MUAC − 0.3142*(triceps skinfold thickness) [24]. MAMC were considered an indicator
of muscle mass. MAMC has been shown to correlate strongly with more accurate dual-
energy X-ray absorptiometry (DXA) measures of lean body mass [25]. Men with BMI
b18.5 and those with missing data on MAMC were excluded (n = 32).
2.2. Cardiovascular risk factors and mobility limitation
Details of measurement and classiﬁcation methods for smoking status, physical
activity, social class, alcohol intake, blood pressure, blood lipids and lung function
(forced expiratory volume in one second [FEV1] in this cohort have been described
[13,26]. Predicted glomerular ﬁltration rate (eGFR) (renal function) was estimated
from serum creatinine using the Modiﬁcation of Diet in Renal Disease equation;
eGFR = 186 × creatinine − 1.154 × age − 0.203. C-reactive protein (CRP) was
assayed by ultrasensitive nephelometry (Dade Behring, Milton Keynes, UK). Preva-
lent diabetes included men with diagnosed diabetes or men with fasting blood glu-
cose ≥7 mmol/l. The men were asked whether they currently had difﬁculty
carrying out any of the four following activities on their own as a result of a long
term health problem: (i) going up or down stairs, (ii) bending down or straightening
up, (iv) keeping one's balance and (iv) walking for a quarter of a mile on the level.
Mobility limitation was deﬁned as men reporting difﬁculty in any one of the above
[27].
2.3. Adiponectin, leptin and NT-proBNP
Plasma adiponectin concentrations were determined using ELISA (R&D systems, UK).
The intra-assay and the inter-assay coefﬁcients of variabilitywere each 7.5%.Wehave pre-
viously shown this method to correlate well with a radioimmunoassay method for
adiponectinmeasurement [20]. Plasma leptin was measured by an ‘in house’ radioimmu-
noassay carefully validated against the commercially available Linco assay, as previously
described [28]. The intra- and inter- assay coefﬁcients of variation were b7% and b10%,respectively, over the sample concentration range. The detection limit of the assay was
0.5 ng/ml which is superior to commercial assays. NT-proBNP was determined using the
Elecsys 2010 electrochemiluminescence method (Roche Diagnostics, Burgess Hill, UK).
Samples were snap-thawed at 37 °C and assayed on the analyzer, which was calibrated
using the manufacturer's reagents. Manufacturer's controls were used to monitor assay
drift, using both a high and low control, with limits of acceptability deﬁned by the manu-
facturer. Low control CV was 6.7% and high control CV was 4.9% [29].
2.4. Follow-up
All men have been followed up from initial examination (1978–1980) for cardio-
vascular morbidity and mortality [30] and follow-up has been achieved for 99% of the
cohort. In the present analyses, all-cause mortality is based on follow-up from re-
screening in 1998–2000 at mean age 60–79 years to June 2010, a mean follow-up pe-
riod of 11 years (range 10–12 years). Information on death was collected through the
established “tagging” procedures provided by the National Health Service registers. A non-
fatal myocardial infarction (MI) was diagnosed according to World Health Organisation
criteria. Evidence of non-fatal MI and HF was obtained by ad hoc reports from general prac-
titioners supplemented by biennial reviews of the patients' practice records (including hos-
pital and clinic correspondence) and from repeated personal questionnaires to surviving
subjects after initial examination through to the end of the study period. Incident non-fatal
HFwas based on a doctor diagnosis of HF fromprimary care records and conﬁrmedby a clin-
ical record review by the Research Team.
2.5. Men with CHD and HF
Themen were asked whether a doctor had ever told them that they had angina or
MI, HF, stroke, diabetes and a number of other CVD conditions. Patient recall of a doc-
tor diagnosis of CHD has been shown to be a valid measure of recording diseases in
this study population [31,32]. The kappa statistics comparing record review with
patient's recall of CHD was 0.82 [31]. On the basis of recall of doctor diagnosis of
CHD (MI, angina, coronary revascularisation) and ECG evidence of deﬁnite MI in
1998–2000 and regular surveillance of general practitioner's records of major non-
fatal MI, or HF occurring before that point, the men were divided into three groups
based on their CHD and HF status:
(i) Men without CHD or HF (n = 3174) as deﬁned in (ii) and (iii) below.
(ii) Those with prevalent diagnosed CHD or ECG evidence of deﬁnite MI but no diag-
nosed HF (N = 860).
(iii) Thosewith doctor diagnosed HF (with or without CHD) conﬁrmed in the primary
care records and conﬁrmed by a review of the clinical features of diagnosed HF
cases (symptoms, signs, treatment response) by the Research team to ensure
they are consistent with European Society of Cardiology recommendations on
diagnosis [33] (n = 86).
2.6. Statistical methods
The distributions of leptin, adiponectin and NT-proBNP were skewed and log
transformation was used. Cox's proportional hazards model was used to assess the
multivariate-adjusted hazards ratio. Overweight (25–29.9 kg/m2) and obesity
(≥30 kg/m2) were deﬁned on the basis of WHO deﬁnitions. Similarly we considered
WC as a categorical variable using three categories b94 cm, 94–101 cm and ≥102 cm.
In multivariate analyses, smoking,social class, physical activity, alcohol intake, diabe-
tes and stroke were ﬁtted as categorical variables; leptin, adiponectin, NT-proBNP
and muscle mass were ﬁtted as continuous variables.
3. Results
During the mean follow-up period of 11 years there were 1340
deaths in all men. Fig. 1 shows the Kaplan-Meier survival estimates by
BMI groups in the three groups of men. Inmenwithout CHD or HF, obe-
sity and normalweightmen showed similar survival rateswith the low-
est rates in overweight men (log rank test p = 0.0008). In both men
with CHD without HF and in men with HF overweight and obesity
were associated with higher survival rates than men with normal
weight [log rank test p = 0.02 and p = 0.07 respectively].
3.1. BMI, body composition, adipokines and NT-proBNP
Table 1 shows the association between BMI and body composition,
adipokines and NT-proBNP in the three groups. In all groups, normal
weight (BMI 18.5–24.9 kg/m2)was strongly associatedwith lowmuscle
mass. In men without CHD or HF over half of the men with normal
weight had low muscle mass compared to just 7% in the obese group.
The prevalence of low muscle mass in normal weight groups increased
to 66% in those with CHD and to over 70% in those with HF. Central
Fig. 1. Kaplan–Meier curves of survival by BMI inmen without CHD or HF, men with CHD
(no HF) and men with HF.
Table 1
BMI and body composition and adipokines according to CHD and heart failure status.
18.5–25 25–29.9 30+ p-trend
Men with no CHD or heart failure (N = 3174)
WC (cms) 87.6 (6.54) 98.3 (6.06) 110.9 (8.22) b0.0001
MAMC (cms) 24.95 (1.88) 26.81 (1.98) 28.49 (2.23) b0.0001
% low muscle
mass
56.7 20.9 7.8 b0.0001
Adiponectin
(μg/ml)*
7.77 (5.14–12.32) 6.48 (4.2–10.33) 5.87
(3.89–9.25)
b0.0001
Leptin
(ng/ml)*
5.70 (3.7–8.35) 9.68 (6.6–13.7) 17.63
(11.4–23.1)
b0.0001
NT-proBNP
(pg/ml)*
87.4 (45–153) 77.5 (38–146) 85.6
(42–167)
0.31
Men with CHD and no heart failure (N = 860)
WC (cms) 88.1 (6.50) 98.6 (5.99) 112.1 (8.19) b0.0001
MAMC (cms) 24.5 (2.03) 26.5 (2.00) 28.2 (2.24) b0.0001
% low muscle
mass
66.4 26.4 7.3 b0.0001
Adiponectin
(μg/ml)**
8.24 (5.44–13.44) 6.49 (3.98–10.89) 5.81
(3.60–8.92)
b0.0001
Leptin
(ng/ml)*
6.75 (4.3–10.2) 10.70 (7.2–15.9) 18.73
(13–27.2)
b0.0001
NT-proBNP
(pg/ml)*
237.5 (112–511) 196.4 (88.5–439.5) 162.3
(71–326)
0.0006
Men with heart failure (N = 86)
WC (cms) 88.4 (7.40) 99.3 (9.23) 113.0 (9.86) b0.0001
MAMC (cms) 24.3 (1.60) 26.2 (2.04) 26.6 (2.56) b0.0001
% low muscle
mass
73.9 31.1 27.8 b0.0001
Adiponectin
(μg/ml)*
15.49 (12.35–19.69) 6.69 (4.18–10.83) 8.50
(5.78–16.53)
0.01
Leptin
(ng/ml)*
5.81 12.30 25.23 b0.0001
NT-proBNP
(pg/ml)*
1236.5 (861–2753) 278.7 (86.5–801) 492.7
(332–1018)
0.05
Mean (standard deviation) unless stated; * geometric mean and interquartile range.
Lowmuscle mass = lowest tertile MAMC.
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all groups; adiponectin decreased signiﬁcantly with increasing BMI.
Normal weight was associated with increased NT-proBNP levels in
those with CHD and especially in those with HF. No association was
seen between BMI and NT-proBNP in those without CHD or HF.3.2. Baseline characteristic by BMI status
Table 2 shows the baseline characteristics by BMI in the three
groups. Obese men were signiﬁcantly the youngest group irrespective
of CHD/HF status and had the lowest rates of smoking. Prevalence of
mobility limitation increased with increasing BMI and was highest in
obese men in all CHD/HF status group. HF patients showed by far the
highest rates of mobility limitation within all BMI groups. CRP and
haemoglobin levels increased signiﬁcantly with increasing BMI in both
groups of men without HF but showed small and non-signiﬁcant in-
crease with BMI in those with HF.
3.3. BMI, body composition, adipocytes, NT-proBNP and mortality
Table 3 shows the association between BMI, body composition, adi-
pocytes, NT-proBNP and mortality separately in the three groups ad-
justed for age. Obesity was associated with the highest risk, albeit
non-signiﬁcant in those without CHD after age-adjustment. By contrast,
among men with CHD normal weight was associated with the highest
mortality with the lowest mortality risk in the overweight group. In
men with HF an inverse association was seen between BMI andmortal-
ity. WC was positively associated with mortality in those without CHD
or HF but no signiﬁcant association was seen in those with CHD. In
men with HF an inverse association was also seen for WC (albeit non-
signiﬁcant). Muscle mass was inversely associated with mortality in
those without HF but less apparent in those with HF. Leptin was posi-
tively association with mortality in men with or without CHD but was
signiﬁcantly inversely associated withmortality in thosewith HF. A for-
mal test for interaction conﬁrmed a signiﬁcant difference in the rela-
tionship between leptin and mortality in men with and without HF
(p b 0.001). Adiponectin showed positive associations with mortality
in all three groups although the trend was weak in those with CHD
Table 2
Baseline characteristics by BMI groups according to CHD and heart failure status.
BMI (kg/m2)
18.5–25 25–29.9 30+ p-trend
Men with no CHD or heart
failure
Age (years) 68.9 (5.62) 68.1 (5.36) 67.8 (5.32) b0.0001
% diabetes 6.5 10.6 18.9 b0.0001
% diagnosed stroke 3.4 4.5 6.6 0.02
% renal dysfunction 10.7 14.4 16.5 0.001
% reported weight loss 14.3 11.8 13.6 0.38
% statins 2.0 2.5 2.9 0.28
% smokers 16.5 11.6 9.9 b0.0001
% inactive 7.4 6.8 16.7 b0.0001
%mobility limitation 18.6 21.5 34.4 b0.0001
FEV1 (L) 2.61 (0.71) 2.68 (0.62) 2.55 (0.64) 0.55
SBP (mmHg) 147.7 (25.02) 151.1 (23.48) 152.6 (22.99) b0.0001
Cholesterol (mmol/l) 6.06 (1.06) 6.09 (1.05) 6.06 (1.10) 0.90
CRP (mg/L)* 1.26
(0.56–2.50)
1.72
(0.85–3.26)
2.48
(1.30–4.70)
b0.0001
Haemoglobin
(g/dL)
14.42 (1.20) 14.69 (1.14) 14.77 (1.07) b0.0001
Men with CHD and no heart failure HF
Age (yrs) 70.9 70.0 68.7 b0.0001
% diabetes 9.6 12.7 19.9 0.003
% diagnosed stroke 13.1 10.5 14.7 0.70
% diagnosed MI 56.8 51.4 52.4 0.34
% silent MI 12.2 12.5 11.5 0.84
% renal dysfunction 19.7 24.7 21.1 0.67
% reported weight loss 26.6 15.5 17.3 0.009
% statins 22.3 28.4 27.2 0.22
% smokers 17.5 10.2 7.4 0.001
% inactive 14.5 18.3 22.1 0.06
% mobility limitation 28.0 36.8 44.0 0.006
FEV1 (L) 2.38 (0.67) 2.48 (0.62) 2.47 (0.53) 0.24
SBP (mmHg) 143.0 (24.66) 145.3 (24.47) 149.6 (24.51) 0.002
Cholesterol (mmol/l) 5.61 (0.98) 5.85 (1.13) 5.82 (1.16) 0.03
CRP (mg/L)* 1.79
(0.72–4.40)
1.95
(1.00–3.86)
2.64
(1.27–5.15)
0.0003
Haemoglobin (g/dl) 14.19 (1.18) 14.50 (1.33) 14.59 (1.21) 0.005
Men with heart failure
Age (yrs) 71.9 72.3 69.5 b0.0001
% diabetes 13.0 15.6 16.7 0.74
% diagnosed stroke 17.4 8.9 0 0.06
% diagnosed MI 30.4 24.4 55.6 0.12
% silent MI 8.7 8.9 5.6 0.74
% renal dysfunction 36.4 33.3 23.5 0.42
% reported weight loss 30.4 24.4 33.3 0.89
% statins 8.7 6.7 22.2 0.20
% smokers 17.5 10.2 7.4 0.05
% inactive 30.4 15.6 29.4 0.74
% mobility limitation 43.4 35.6 72.2 0.09
FEV1 (L) 2.15 (0.79) 2.21 (0.66) 2.25 (0.53) 0.66
SBP (mmHg) 138.3 (26.80) 147.2 (24.63) 136.8 (30.78) 0.98
Cholesterol (mmol/l) 5.98 (0.89) 5.78 (1.07) 5.98 (1.09) 0.78
CRP (mg/L)* 2.20
(0.68–11.20)
2.45
(1.00–4.07)
2.53
(1.49–3.83)
0.83
Haemoglobin (g/dl) 14.40 (1.28) 14.80 (1.17) 14.46 (0.76) 0.90
SBP systolic blood pressure; *Geometric mean and interquartile range;
Renal dysfunction = eGFR b60 ml/min per 1.73 m2.
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ity in all groups, lending external validity to our ﬁndings.
3.4. BMI and mortality
Table 4 shows the relative risk of mortality by BMI groups adjusted
sequentially for confounders and possible mechanisms. Inmen without
CHD/HF a signiﬁcant positive associationwas seen between obesity and
mortality after adjustment for muscle mass. In men with CHD (no HF),
overweight and obesity were associated with signiﬁcantly lower risk
of mortality after adjustment for potential confounders and pre-
existing disease (model 1) which was attenuated after adjustment for
muscle mass (model 2). Further adjustment for NT-proBNP andadiponectin reduced the difference further, but only modestly. In a sen-
sitivity analysis conﬁned to men with MI only, a similar pattern was
seen. In men with HF a signiﬁcant inverse association was seen even
after adjustment for lifestyle characteristics pre-existing disease muscle
mass and NT-proBNP (model 3). The inverse association was strength-
ened after adjustment for mobility limitation (p = 0.006). Adjustment
for adiponectin (model 4) attenuated the inverse association and ad-
justment for leptin abolished the inverse association between BMI and
mortality in those with HF (model 5).
4. Discussion
In this study of older men in the general population we were able to
examine the BMI-mortality relationship separately in those with and
without CHD or HF within the same older population and the ﬁndings
suggest that the obesity paradox is largely seen in those with CHD and
particularly in those with HF. Obesity was associated with lower risk
of mortality compared to normal weight in men with CHD or HF al-
though the lowest mortality in those without CHD or HF was seen in
the overweight group. Our ﬁndings are consistent with the vast major-
ity of studies that have demonstrated the obesity paradox in popula-
tions with CHD or HF based on BMI [1–8] and extends previous
reports by examining the role of several possible factors which have
been proposed to help explain this paradox including muscle mass,
NT-proBNP and adipokines which have not been widely examined.
4.1. Muscle mass and NT-proBNP
Part of the explanation for the obesity paradoxmay be due to the use
of BMI to deﬁne obesity, which does not take into account lean muscle
mass. We have shown that the vast majority of men with normal
body weight had low muscle mass and the prevalence of low muscle
mass increased appreciably in the presence of CHD and HF. Lowmuscle
mass was associated with increased mortality in those without HF irre-
spective of CHD status. The lower risk associated with overweight and
obesity in those with CHD was attenuated after adjustment for muscle
mass. In men with HF however the inverse association between BMI
and mortality persisted. Few studies have examined the role of muscle
mass although one study showed the obesity paradox to persist in
thosewith CHD even after taking into accountmusclemass [8]. Howev-
er patientswith CHD in that study included thosewithHF. Thus the per-
sistence of lower risk associated with obesity may have been due to the
high prevalence of patients with HF in this group. BMI related inversely
to NT-proBNP only in those with CHD or HF but not in men without
CHD/HF. It is well recognised that obesity is associated with lower NT-
proBNP. The mechanisms are still unclear but it has been proposed
that adipose tissue contains an abundance of natriuretic peptide binding
sites, leading to increased clearance of NT-proBNP in obese patients
who have larger stores of adipose tissue [34]. However, further adjust-
ment for NT-proBNP made minor differences in those with CHD once
muscle mass was taken into account. Men with HF and low BMI had
by far the highest levels of NTproBNP. This is consistent with the specu-
lation that natriuretic peptides with their lipolytic actions may be re-
sponsible for the loss of adipose tissue observed in cachetic HF
patients [35]. The inverse association between BMI and mortality in
those with HF, however, was not explained by lean muscle mass or
NT-proBNP.Wemeasured leanmusclemass bymeans ofMAMC and al-
though a correlation between DXA and MAMC has been described [25],
in patients with HF the muscle component related to lower limbs may
play a far more important role than that of the arms. Patients with HF
often exhibit some degree of muscle wasting restricted to the lower
limbs so MUAC may not be a good indicator of skeletal muscle wasting
in HF patients except when HF is more advanced in the cachectic status
[35]. In agreementwith this, mobility limitation, which is strongly asso-
ciated with loss of lower limb muscle strength [36] was indeed shown
to be strongly associated with HF. We observed greater difference in
Table 3
Adiposity measures, muscle mass, adipokines, NT-proBNP and age-adjusted hazards ratio (95%CI) total mortality inmen with no CHD or HF, menwith CHD (no HF) and inmen with HF.
Men with no CHD or HF (n = 3174) Men with CHD and no HF (n = 860) Men with HF (n = 86)
Mortality rate/1000 per-yrs 28.7 49.3 90.1
BMI (kg/m2) N No of cases Age-adjusted N No of cases Age-adjusted N No of cases Age-adjusted
b25 990 304 1.00 229 119 1.00 23 19 1.00
25–29.9 1698 446 0.88 (0.76,1.02) 440 178 0.74 (0.58,0.93) 45 29 0.52 (0.29,0.94)
30+ 486 154 1.17 (0.97,1.42) 191 81 0.88 (0.67,1.75) 18 10 0.47 (0.22,1.01)
p-trend P = 0.43 P = 0.25 P = 0.04
WC
b94 1246 346 1.00 288 141 1.00 27 20 1.00
94–102 1057 280 0.99 (0.85,1.16) 287 114 0.81 (0.63,1.04) 28 17 0.51 (0.26,0.99)
N102 871 278 1.23 (1.05,1.44) 285 123 1.00 (0.78,1.28) 31 21 0.63 (0.34,1.18)
p-trend P = 0.02 P = 0.67 P = 0.23
Muscle Mass
(MAMC)
1 (low) 1057 398 1.00 287 158 1.00 30 21 1.00
2 1060 273 0.76 (0.65,0.88) 286 113 0.74 (0.54, 0.94) 27 17 1.16 (0.60, 2.26)
3 (high) 1057 233 0.71 (0.60,0.83) 287 107 0.76 (0.59, 0.98) 29 20 0.88 (0.48, 1.64)
p-Trend P b 0.0001 P = 0.03 P = 0.68
Leptin
1 (low) 980 358 1.00 258 110 1.00 27 22 1.00
2 961 298 0.99 (0.84, 1.18) 252 108 1.11 (0.85,1.45) 26 15 0.49 (0.26,0.95)
3 (high) 966 165 1.21 (1.03,1.43) 254 122 1.40 (1.08,1.81) 27 16 0.35 (0.18,0.68)
p-Trend P = 0.02 P = 0.01 P = 0.002
Adiponectin
1 (low) 1010 234 1.00 269 106 1.00 28 14 1.00
2 1011 276 1.13 (0.95,1.34) 268 112 0.98 (0.75,1.29) 27 19 1.60 (0.80,3.22)
3 (high) 1012 352 1.27 (1.07, 1.51) 269 139 1.19 (0.92,1.54) 27 21 2.30 (1.17,4. 50)
p-trend P = 0.005 P = 0.18 P = 0.02
NT-proBNP
1 (low) 951 170 1.00 252 73 1.00 25 12 1.00
2 942 224 1.09 (0.89,1.34) 251 98 1.26 (0.93,1.71) 26 18 1.24 (0.58,2.65)
3 (high) 951 408 1.82 (1.50,2.20) 253 165 2.38 (1.78,3.18) 25 20 2.75 (1.32,5.72)
p-trend P b 0.0001 P b 0.0001 P = 0.001
p-trend— test for trend across groups.
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between HF patients and non HF patients but adjustment for mobility
limitation did not explain the inverse association between BMI
and mortality in HF patients since obese patients had the highest
prevalence.4.2. Adipokines
We also investigated the role of adipokines (adiponectin and leptin)
in explaining the paradoxical link in HF. HF patients with low BMI
showed by far the highest levels of adiponectin which may reﬂect low
skeletal muscle strength [37]. The inverse association between BMI
and mortality was only partially attenuated after adjustment for
adiponectin. Leptin however, appeared to explain the obesity paradox
in men with HF. Leptin was positively associated with mortality in
men without CHD or HF and in men with CHD (no HF) which is consis-
tent with a previous report in those with established atherosclerosis
[38]. However, in those with HF a signiﬁcant inverse association was
seen with mortality, and there was clear statistical heterogeneity. This
unexpected association is consistent with clinical studies suggesting
that leptin may have protective effects in those with HF through
neutralising the deleterious effects of the proinﬂammatory cytokine tu-
mour necrosis factorα on themyocardium inHFpatients leading to bet-
ter survival [18,39]. Alternatively high leptin levels in those with HF are
likely to be secondary to increased fat. Leptin has an important role in
energy metabolism and in lean and fat mass and appetite regulation
[40]. Cardiac cachexia (wasting) observed in end stage HF is associated
with a decrease of fat mass in addition to a reduced lean muscle mass
[41]. Loss of weight and fat leads to a decrease in leptin and leptin levelshave been shown to be lower in cachetic HF patients compared to
noncachetic HF patients [42]. Thus low leptin in those with HF may re-
ﬂect loss of adipose tissue due to cachexia which is associated with re-
duced survival [42]. Of interest, low leptin levels have been associated
with worsening immune function too [43], so that individuals with
low leptin may be less able to buffer against infections or inﬂammatory
insults.
4.3. Waist circumference
The association between WC and mortality in CHD patients in con-
trast to BMIhave found to bepositive [14] or null [9].We showed no sig-
niﬁcant association between WC and mortality in those with CHD
which is consistent with a previous study in patients with MI [9]. The
lack of association between central adiposity and mortality in those
with CHD in the present study is in keeping with the ﬁndings that the
inverse association seen for BMI in those with CHD may reﬂect muscle
mass. Data on WC and mortality in HF patients are limited. Although
one study reported a positive association [44] an inverse association be-
tweenWC and mortality has also been previously reported [45] as was
observed in our studywhichmay reﬂect loss of fatmass due to cachexia.
4.4. Strengths and limitations
The strengths of this study include its representative sampling of
older men aged 60–79 years with high follow-up rate, good characteri-
zation of CVD status and the availability of a wide range of adiposity
measures, CV risk factors and biological markers including adipokines
and NT-proBNP. Muscle mass was estimated from MAMC and we did
Table 4
BMI and adjusted hazards ratio (95%CI) total mortality in men by CHD and heart failure
status.
BMI (kg/m2) P for Low vs high
(b25 vs ≥25)
18.5–24.9 25–29.9 30+ trend
No CHD and no HF
Model 1 1.00 0.88 (0.76,1.02) 1.01 (0.83,1.24) P = 0.67 0.91
(0.79,1.05)
Model 2 1.00 0.99 (0.84,1.16) 1.25 (1.00,1.59) P = 0.13 1.01
(0.87,1.18)
Model 3 1.00 0.97 (0.82,1.13) 1.19 (0.95,1.50) P = 0.27 0.99
(0.85,1.16)
Model 4 1.00 1.00 (0.84,1.19) 1.24 (0.85,1.43) P = 0.13 1.04
(0.88,1.21)
CHD and no HF
Model 1 1.00 0.71 (0.56,0.91) 0.77 (0.57,1.04) P = 0.04 0.72
(0.57,0.90)
Model 2 1.00 0.80 (0.62,1.03) 0.96 (0.68,1.35) P = 0.60 0.81
(0.63,1.04)
Model 3 1.00 0.78 (0.61,1.01) 0.96 (0.68,1.36) P = 0.48 0.81
(0.63,1.04)
Model 4 1.00 0.78 (0.60,1.02) 0.95 (0.68,1.35) P = 0.59 0.81
(0.62,1.05)
HF
Model 1 1.00 0.57 (0.28,1.16) 0.41 (0.16,1.09) P = 0.04 0.44
(0.21,0.90)
Model 2 1.00 0.66 (0.29,1.52) 0.47 (0.17,1.35) P = 0.09 0.49
(0.21,1.13)
Model 3 1.00 0.63 (0.26,1.52) 0.35 (0.12,1.02) P = 0.05 0.54
(0.23,1.24)
Model 4 1.00 0.78 (0.30,2.06) 0.44 (0.14,1.39) P = 0.15 0.66
(0.26,1.69)
Model 5 1.00 0.82 (0.31,2.20) 0.99 (0.27,3.71) P = 0.98 0.84
(0.31,2.24)
Model 1 = adjusted for age, smoking, alcohol intake, social class, physical activity,
prevalent diabetes and stroke.
Model 2 = Model 1 + muscle mass.
Model 3 = Model 1 + muscle mass + NT-proBNP.
Model 4 = Model 1 + muscle mass + adiponectin.
Model 5 = Model 1 + muscle mass + leptin.
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raphy scanning or magnetic resonance imaging (MRI). However MAMC
has been shown to correlate strongly with more accurate measures of
lean mass, measured by DXA [25]. Our HF cases are based on general
practitioners’ reporting however their validity is supported by the
close agreement of the incidence and determinants of HF in this study
population with those of other sources [28,29]. Although we did not
have data available on many factors related to mortality in HF patients
such as left ejection fraction and the New York Heart Association
(NYHA) functional class, previous studies have shown the inverse asso-
ciation between BMI and total mortality to be independent of left ven-
tricular ejection fraction and the NYHA functional class [3]. Moreover
obese (not lean) patients in our study showed the highest rates of mo-
bility limitation an indicator of functional limitation which is consistent
with the ﬁndings in the CHARM Study that obese subjects had the
highest prevalence of NYHA class III and IV [3]. We did not have infor-
mation on obstructive sleep apnoea (OSA) which is highly prevalent
in patients with HF and is associated with worsening prognosis [46].
However, obesity is considered a risk factor for OSA and a recent study
of sleep apnoea in HF patients has shown obesity (rather than leanness)
to be associated with OSA [46]. Thus OSA is unlikely to explain the high
mortality rates in those with low BMI. Our study was carried out in a
predominantly white Caucasianmale population and we cannot gener-
alise ourﬁndings to olderwomen or other ethnic groups. The number of
menwith conﬁrmedHF in our studywas small and further large studies
in HF are needed to conﬁrm the ﬁndings of leptin and mortality in HF.
Moreover our study cannot assess the nature of the relationship
between leptin and mortality in those with HF.5. Conclusion
In this older population, the obesity paradox (increased survival in
those with higher BMI) is commonly seen in those with CHD or HF.
The lower risk of mortality associated with excess body weight in men
with CHD without HF appears largely associated with higher muscle
mass. In men with HF, an additional loss of fat mass as exempliﬁed by
low leptin appears to explain the inverse association. Whether lower
leptin directly or indirectly (by virtue of its association with fat mass)
explains higher mortality in HF remains to be elucidated.References
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